Astellas Gene Therapies, INC. a Delaware Corporation
Based in CA
AI Overview
With $860K in lobbying spend across 14 quarterly filings, Astellas Gene Therapies, INC. a Delaware Corporation is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2020 to 2024.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $140K |
| 2021 | $90K |
| 2022 | $270K |
| 2023 | $360K |
| 2024 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Astellas Gene Therapies, INC. a Delaware Corporation disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid
Issues related to expanding access for cell and gene therapies, Medicare, Medicaid, and other general healthcare issues
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2021, Elijah Cummings Lower Drug Costs Now Act (H.R. 3)
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.